Q-omics provides the consensus-scored CAPN10-DT profile across patient tissues and cancer cell-line models. CAPN10-DT expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CAPN10-DT is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, CAPN10-DT RNA expression shows 19,664 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where CAPN10-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CAPN10-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CAPN10-DT survival associations across molecular data types. CAPN10-DT RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CAPN10-DT RNA expression–survival associations across cancer types. High CAPN10-DT expression shows unfavorable associations in KIRC, ACC, LIHC, UCEC and UVM, but favorable associations in KICH. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CAPN10-DT RNA expression.
This table summarizes CAPN10-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CAPN10-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CAPN10-DT shows higher tumor expression in COAD, BLCA, LIHC, STAD, HNSC and READ. The COAD box plot shows higher CAPN10-DT RNA expression in tumor versus normal tissue (log2 FC = +0.799, t-test p < 0.001).
This table shows molecular features associated with CAPN10-DT in patient tissues and cancer cell lines. In patient samples, CAPN10-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
